$0.43
arrow_drop_up9.41%Key Stats | |
---|---|
Open | $0.39 |
Prev. Close | $0.39 |
EPS | -0.36 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
Market Cap | $41.97M |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 0.39 | 0.46 |
52 Week Range | 0.20 | 1.81 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -0.36 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference - GlobeNewswire
Unicycive Therapeutics Announces Initial Positive Patient - GlobeNewswire
Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday - Greenbrier Companies (NYSE:GBX) - Benzinga
Unicycive Therapeutics Joins Russell Microcap® Index
Unicycive Therapeutics Achieves Study Objective in Oxylanthanum Carbonate (OLC) Pivotal Clinical Trial
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress